Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guardant HealthMEX:GH 13 EV-to-FCF is -88.10 as of Jul. 15, 2026. GuruFocus rates MEX:GH with a GF Score™ of 13/100 and a GF Value™ of MXN989.11 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Guardant Health ranks worse than 1010100% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Guardant Health's Enterprise Value is MXN382,483 Mil.
Guardant Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-4,341 Mil. Therefore, Guardant Health's EV-to-FCF for today is -88.10.
The historical rank and industry rank for Guardant Health's EV-to-FCF or its related term are showing as below:
MEX:GH'
s EV-to-FCF Range Over the Past 10 Years
Min: -119.88 Med: -34.24 Max: -6.46
Current: -92.05
During the past 10 years, the highest EV-to-FCF of Guardant Health was -6.46. The lowest was -119.88. And the median was -34.24.
MEX:GH's EV-to-FCF is ranked worse than 100% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.47
vs MEX:GH: -92.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guardant Health's PE Ratio (TTM) for today is calculated as:
Guardant Health's share price for today is MXN2590.00.
Guardant Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-62.066.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Guardant Health EV-to-FCF Related Terms
Guardant Health EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Guardant Health's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Guardant Health's EV-to-FCF falls into.
Guardant Health's current Enterprise Value is MXN382,483 Mil.
Guardant Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-4,341 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (MEX:GH) has a EV-to-FCF of -88.10 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guardant Health and its competitors. According to the industry distribution chart, Guardant Health ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry.
Is Guardant Health's EV-to-FCF too high?
Guardant Health's current EV-to-FCF is -88.10. Based on the distribution chart, Guardant Health ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Guardant Health has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's EV-to-FCF compare to LH and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #999999 out of 99 companies for EV-to-FCF. This places Guardant Health in the lower half of its industry. The industry median EV-to-FCF is 25.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 25.47, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guardant Health and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 25.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardant Health's current EV-to-FCF is -88.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (MEX:GH) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN989.11, compared to a current price of MXN2,590.00 — trading 161.9% above its estimated fair value. The current EV-to-FCF is -88.10. Guardant Health's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Guardant Health (MEX:GH), the current EV-to-FCF is -88.10 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (MEX:GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of MXN2,590.00 is trading 161.9% above its estimated GF Value™ of MXN989.11.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for MEX:GH:
EV-to-FCF: -88.10
GF Value™: MXN989.11 vs. price of MXN2,590.00 (161.9% above fair value)
No single metric tells the full story. See the MEX:GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
13GF Score
Get the complete analysis for MEX:GH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GH has been successfully added to your 
